Menü
Dieses Wertpapier wird aktuell nicht bei uns gehandelt
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

QIAGEN launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe following CE marking
QIAGEN launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe following CE marking


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has obtained CE marking for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro

QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus
QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the

Premier Inc. Survey: More Than Two-Thirds of Senior Living Facilities Say They Can’t Access Personal Protective Equipment Needed for COVID-19 Containment Plans
Premier Inc. Survey: More Than Two-Thirds of Senior Living Facilities Say They Can’t Access Personal Protective Equipment Needed for COVID-19 Containment Plans


Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that more than two-thirds of senior living facilities in the United States cannot obtain

Chemed Corporation’s Board of Directors Authorizes an Additional $250 Million for Stock Repurchase
Chemed Corporation’s Board of Directors Authorizes an Additional $250 Million for Stock Repurchase


Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional $250 million for stock repurchase under Chemed’s existing share repurchase program

QIAGEN Gains BARDA Funding for Approval Process of QIAstat-Dx Test Kit for SARS-CoV-2 Coronavirus
QIAGEN Gains BARDA Funding for Approval Process of QIAstat-Dx Test Kit for SARS-CoV-2 Coronavirus


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will develop a new QIAstat-Dx test kit to differentiate the novel SARS-CoV-2 coronavirus from 21 other serious respiratory

Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy
Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy


Novocure (NASDAQ: NVCR) announced today that preclinical data on Tumor Treating Fields in combination with anti-PD-1 therapy were published in the peer-reviewed journal, Cancer Immunology,

Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance


Regulatory News:



Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The

Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose
Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose


Regulatory News:



Die Vifor Pharma Gruppe erzielte 2019 ein starkes finanzielles und operatives Ergebnis dank Fokus auf die drei strategischen Wachstumstreiber und gezielten Investitionen in die

Charles River Laboratories To Participate In Barclays Global Healthcare Conference
Charles River Laboratories To Participate In Barclays Global Healthcare Conference


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will participate in the Barclays Global Healthcare Conference. The Company will present on Wednesday, March 11th

Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen
Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen


LivaNova PLC (NASDAQ:LIVN), ein marktführendes medizintechnisches Innovationsunternehmen, gab heute bekannt, dass sein System Vagus Nerve Stimulation Therapy® (VNS Therapy) Symmetry™ die

LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression
LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy® (VNS Therapy) System, Symmetry™, earned CE Mark approval

Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews, M.D., Ph.D., to its Board of Directors, effective February 28, 2020. Dr. Andrews is

Morphosys: Positive Nachrichten – jetzt fließt Geld!
Morphosys: Positive Nachrichten – jetzt fließt Geld!

Morphosys (WKN: 663200) kann sich unmittelbar auf eine Zahlung von 750 Millionen US-Dollar durch den Pharmakonzern Incyte (WKN: 896133) freuen. Diese wird fällig, sobald der globale Kollaborations-

Qiagen: Heiße Übernahme-Wette geht auf
Qiagen: Heiße Übernahme-Wette geht auf

Ungeahnte Freudensprünge bei Qiagen (WKN: A2DKCH): Weil jetzt doch noch ein Übernahmeangebot kommt, gewinnt die Aktie heute um rund 18 Prozent auf 37,5 Euro – der größte Tageszuwachs seit zwei

ICON plc to Present at Barclays Global Healthcare Conference 2020
ICON plc to Present at Barclays Global Healthcare Conference 2020


ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr

Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings
Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings


Regulatory News:



Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This investment

Premier Inc. Survey Finds 86 Percent of Health Systems Are Concerned About Personal Protective Equipment Shortages Due to Coronavirus
Premier Inc. Survey Finds 86 Percent of Health Systems Are Concerned About Personal Protective Equipment Shortages Due to Coronavirus


Premier Inc. (NASDAQ: PINC) today released survey results finding that 86 percent of U.S. hospitals and health systems are concerned about their supply of face masks and other personal protective

QIAGEN Announces 20-F Annual Report Filing for 2019 Results
QIAGEN Announces 20-F Annual Report Filing for 2019 Results


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended

Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update
Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update


Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2019, highlighting continued commercial execution, strengthening financial performance and

LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression
LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with Verily, an Alphabet company, to capture measures of depression

QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2
QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has shipped its newly developed QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China for evaluation. The

Healthcare Improvement Company Premier Inc. to Present at Raymond James 41st Annual Institutional Investors Conference in Orlando on March 3
Healthcare Improvement Company Premier Inc. to Present at Raymond James 41st Annual Institutional Investors Conference in Orlando on March 3


Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that its CEO, Susan DeVore, and Chief Administrative and Financial Officer, Craig McKasson, will present at

Premier Inc. Celebrates a Year of Success in Eliminating Drug Shortages
Premier Inc. Celebrates a Year of Success in Eliminating Drug Shortages


Premier Inc. (NASDAQ: PINC) today released an annual report on its national drug shortage programs, detailing key accomplishments and successful outcomes that have been achieved in collaboration

LivaNova Reports Fourth Quarter and Full-Year 2019 Results
LivaNova Reports Fourth Quarter and Full-Year 2019 Results


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019.



For the fourth quarter of

LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification
LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device